[Biotech&Pharma] Catalent To Buy Cell Therapy CDMO MasTherCell For $315M

Browse By

Catalent Inc (NYSE: CTLT), a contract development and manufacturing organization, or CDMO, that provides services for the development of drugs, biologics, gene therapies and consumer health products, said Monday it has agreed to buy MasTherCell Global for $315 million in cash.

MasTherCell is a privately held cell and gene therapy CDMO that has the backing of Great Point Partners, SFPI-FPIM and Organogenesis Holdings Inc (NASDAQ: ORGO).

“MaSTherCell extends our leadership position in the biotech industry, complements our leading gene therapy offering, and allows us to deliver comprehensive development, manufacturing, analytical, fill-finish, and clinical supply solutions for innovators across the large molecule space,” Catalent CEO John Chiminski said in …

Full story available on Benzinga.com

Source Benzinga

Disclaimer: All posts made on this website are provided for information purposes only. None of the information here is intended as investment advice, as an offer or solicitation of an offer to buy or sell, or as a recommendation, endorsement, or sponsorship of any security, Company, or fund. Before making an investment decision, you should seek the advice of a qualified and registered securities professional. The author is not paid to share this information. Cannabis Investment Group is not paid to share this information and has no business relationship other than shareholder with any company whose stock is mentioned in this article.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.